Researchers developed a biomimetic mRNA delivery platform that restores PTEN expression in colorectal tumor models and enhances anti‑tumor immune responses. The system uses targeted delivery vehicles to achieve tumor‑cell uptake and reconstitute a key tumor suppressor, enabling synergistic effects with immune activation. Preclinical data show restored PTEN signaling correlates with reduced tumor growth and improved immune infiltration. The approach illustrates growing sophistication in mRNA therapeutics beyond vaccine applications: engineering delivery vehicles to reprogram tumor biology directly and sensitize cancers to immunotherapy. The work may open new therapeutic combinations and informs translational considerations for dosing, biodistribution and safety profiling.